[go: up one dir, main page]

EP0914123A4 - Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t - Google Patents

Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t

Info

Publication number
EP0914123A4
EP0914123A4 EP97927902A EP97927902A EP0914123A4 EP 0914123 A4 EP0914123 A4 EP 0914123A4 EP 97927902 A EP97927902 A EP 97927902A EP 97927902 A EP97927902 A EP 97927902A EP 0914123 A4 EP0914123 A4 EP 0914123A4
Authority
EP
European Patent Office
Prior art keywords
thalidomide
prodrugs
modulators
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97927902A
Other languages
German (de)
English (en)
Other versions
EP0914123A1 (fr
Inventor
Robert E Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prototek Inc
Original Assignee
Prototek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prototek Inc filed Critical Prototek Inc
Publication of EP0914123A1 publication Critical patent/EP0914123A1/fr
Publication of EP0914123A4 publication Critical patent/EP0914123A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97927902A 1996-05-29 1997-05-29 Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t Withdrawn EP0914123A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1855896P 1996-05-29 1996-05-29
US18558P 1996-05-29
PCT/US1997/009421 WO1997045117A1 (fr) 1996-05-29 1997-05-29 Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t

Publications (2)

Publication Number Publication Date
EP0914123A1 EP0914123A1 (fr) 1999-05-12
EP0914123A4 true EP0914123A4 (fr) 2000-10-11

Family

ID=21788567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97927902A Withdrawn EP0914123A4 (fr) 1996-05-29 1997-05-29 Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t

Country Status (5)

Country Link
EP (1) EP0914123A4 (fr)
AU (1) AU3224997A (fr)
CA (1) CA2256669A1 (fr)
CZ (1) CZ389398A3 (fr)
WO (1) WO1997045117A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
CA2370245A1 (fr) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Composes de promedicaments anti-tumoraux actives par des enzymes
US6613879B1 (en) 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE19926233C1 (de) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Verfahren zur Herstellung von Thiazolidin
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
CN101690815A (zh) 2000-03-31 2010-04-07 普罗西迪恩有限公司 二肽基肽酶iv酶活性抑制剂的新用途
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
EP1389203B8 (fr) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogues de thalidomide utilises comme inhibiteurs de l'angiogenese
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
SK3622004A3 (sk) 2002-02-28 2005-02-04 Prosidion Limited Inhibítory DPIV na báze glutaminylu
EP1620091B1 (fr) 2003-05-05 2010-03-31 Probiodrug AG Inhibiteurs de glutaminyl-cyclase
EP2206496B1 (fr) 2003-05-05 2014-09-17 Probiodrug AG Criblage d'inhibiteurs de la formation d'acide pyroglutamique dans le peptide amyloide beta
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
AU2004274474B2 (en) 2003-09-17 2011-03-10 Arnold Brossi Thalidomide analogs as TNF-alpha modulators
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US7462599B2 (en) 2003-10-15 2008-12-09 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018496A1 (fr) * 1991-04-17 1992-10-29 Grünenthal GmbH Nouveaux derives de la thalidomide, procede de fabrication et utilisation desdits derives dans des medicaments
WO1997037988A1 (fr) * 1996-04-09 1997-10-16 Grünenthal GmbH Promedicaments acyles de la n-hydroxymethylthalidomide a effet immunomodulateur

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229997A (ja) * 1985-04-08 1987-02-07 Sankyo Co Ltd Ｃ末端にプロリンアミドを有するペプチドの製法
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018496A1 (fr) * 1991-04-17 1992-10-29 Grünenthal GmbH Nouveaux derives de la thalidomide, procede de fabrication et utilisation desdits derives dans des medicaments
WO1997037988A1 (fr) * 1996-04-09 1997-10-16 Grünenthal GmbH Promedicaments acyles de la n-hydroxymethylthalidomide a effet immunomodulateur

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'AMATO R J ET AL: "Thalidomide is an inhibitor of angiogenesis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1994 APR 26) 91 (9) 4082-5., XP002917515 *
GUCKIAN, M. (1) ET AL: "Thalidomide analog 3052 reduces NK activity and PHA-induced proliferation in vitro.", IMMUNOLOGY, (1996) VOL. 89, NO. SUPPL. 1, PP. 34. MEETING INFO.: JOINT CONGRESS OF THE BRITISH SOCIETY FOR IMMUNOLOGY AND THE BIOCHEMICAL SOCIETY HARROGATE, ENGLAND, UK DECEMBER 10-13, 1996, XP000917548 *
See also references of WO9745117A1 *

Also Published As

Publication number Publication date
EP0914123A1 (fr) 1999-05-12
AU3224997A (en) 1998-01-05
CA2256669A1 (fr) 1997-12-04
CZ389398A3 (cs) 1999-07-14
WO1997045117A1 (fr) 1997-12-04

Similar Documents

Publication Publication Date Title
EP0914123A4 (fr) Prodrogues du thalidomide et procedes d'utilisation desdites prodrogues comme modificateurs de cellule t
GB2317141B (en) Compaction methods and apparatus
GB2313248B (en) Headphone apparatus
EP0894885B8 (fr) Procédé et dispositif pour le moulage d'un mélange de fibres
HUP9904009A3 (en) Method and novel compounds for use therein
IL129389A0 (en) Compounds and methods for diagnsosis of tuberculosis
GB2314741B (en) Encryption apparatus
ZA971412B (en) Benzothiophenes formulations containing same and methods
GB2312600B (en) Audio apparatus
GB9712752D0 (en) Disc clamping apparatus
AU2858697A (en) Odour removal apparatus and/or methods
AU7758698A (en) Method and apparatus for distributing long fibers
AU8287798A (en) Adsorption apparatus and methods
AU2500797A (en) Methods of modulating t-cell activation
GB2315379B (en) Non-linear filter apparatus
GB2320149B (en) Modulators
AU3423397A (en) Therapeutic methods and compositions for use therein
GB9823314D0 (en) Methods and apparatus
GB2332771B (en) Audio apparatus
HU1001U (en) Set of device
GB9904847D0 (en) Compaction methods and apparatus
AU2002100822A4 (en) Apparatus and methods for assessment of neuromusclar function
GB9607110D0 (en) Benzothiopenes formulations containing same and methods
AUPN768596A0 (en) Holding apparatus
GB9703026D0 (en) Audio tester apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A

A4 Supplementary search report drawn up and despatched

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE DK FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001114